Eliezer J Barreiro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10950372/publications.pdf

Version: 2024-02-01

176 papers	8,842 citations	66234 42 h-index	48187 88 g-index
184 all docs	184 docs citations	184 times ranked	10888 citing authors

#	Article	IF	Citations
1	Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Current Medicinal Chemistry, 2007, 14, 1829-1852.	1.2	930
2	The Methylation Effect in Medicinal Chemistry. Chemical Reviews, 2011, 111, 5215-5246.	23.0	671
3	Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design. Current Medicinal Chemistry, 2005, 12, 23-49.	1.2	563
4	From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’. Mini-Reviews in Medicinal Chemistry, 2009, 9, 782-793.	1.1	498
5	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. Journal of Medicinal Chemistry, 2018, 61, 5805-5821.	2.9	343
6	Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1108-1119.	1.1	266
7	Î²-lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2020, 208, 112829.	2.6	227
8	Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole##This paper represents contribution # 36 of the LASSBio, UFRJ (Br.) (LASSBio,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td (htt Chemistry, 2000, 35, 187-203.	2.6	195
9	Synthesis and evaluation of analgesic, antiinflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 189-199.	2.6	188
10	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic and Medicinal Chemistry, 2009, 17, 74-84.	1.4	187
11	Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3067-3073.	1.4	174
12	Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2003, 11, 2051-2059.	1.4	168
13	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	1.0	140
14	New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2004, 12, 3149-3158.	1.4	125
15	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2014, 71, 1-14.	2.6	109
16	Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7525-7545.	2.9	105
17	Further Bioactive Piperidine Alkaloids from the Flowers and Green Fruits ofCassiaspectabilis. Journal of Natural Products, 2004, 67, 908-910.	1.5	104
18	Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres:Â A New Class of Potent and Selective Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1144-1152.	2.9	101

#	Article	IF	Citations
19	Medicinal Chemistry of N-Acylhydrazones: New Lead-Compounds of Analgesic, Antiinflammatory and Antithrombotic Drugs. Current Medicinal Chemistry, 2006, 13, 167-198.	1.2	95
20	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 641-652.	1.4	94
21	Os produtos naturais e a quÃmica medicinal moderna. Quimica Nova, 2006, 29, 326-337.	0.3	93
22	Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorganic and Medicinal Chemistry, 2005, 13, 3431-3437.	1.4	87
23	Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of N-acylhydrazone Derivatives. Molecules, 2013, 18, 11683-11704.	1.7	82
24	Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: New lead-agents with analgesic and antipyretic properties. Bioorganic and Medicinal Chemistry, 2006, 14, 7924-7935.	1.4	80
25	Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. European Journal of Medicinal Chemistry, 2009, 44, 4004-4009.	2.6	71
26	Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1169-1172.	1.0	70
27	Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 4807-4813.	1.4	67
28	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	1.4	62
29	Synthesis and antinociceptive properties of new structurally planned imidazo[1,2-a]pyridine 3-acylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 225-235.	2.6	61
30	Synthesis and anti-platelet activity of novel arylsulfonateâ€“acylhydrazone derivatives, designed as antithrombotic candidates. European Journal of Medicinal Chemistry, 2008, 43, 348-356.	2.6	60
31	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 2421-2433.	1.4	59
32	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 1925-1935.	1.4	57
33	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. European Journal of Medicinal Chemistry, 2013, 59, 64-74.	2.6	57
34	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	2.6	57
35	Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2010, 18, 5007-5015.	1.4	53
36	Biodiversidade: fonte potencial para a descoberta de fÃ¡rmacos. Quimica Nova, 2009, 32, 679-688.	0.3	51

#	Article	IF	Citations
37	A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 3159-3166.	1.4	50
38	Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues. PLoS ONE, 2014, 9, e85380.	1.1	50
39	New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorganic and Medicinal Chemistry, 2005, 13, 4184-4190.	1.4	48
40	Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4963-4966.	1.0	48
41	Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H2LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H2LASSBio-1064) and Their Zinc(II) Complexes. Molecules, 2011, 16, 6902-6915.	1.7	48
42	Design and Synthesis of Novel Potent Antinociceptive Agents: Methyl-imidazolyl N-Acylhydrazone Derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 2243-2248.	1.4	47
43	A quÃmica medicinal de N-acilidrazonas: novos compostos-protÃ³tipos de fÃ¡rmacos analgÃ©sicos, antiinflamatÃ³rios e anti-trombÃ³ticos. Quimica Nova, 2002, 25, 129-148.	0.3	42
44	Design, synthesis, and pharmacological evaluation of new neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives with in vivo hypnotic and analgesic profile. Bioorganic and Medicinal Chemistry, 2006, 14, 632-640.	1.4	41
45	Synthesis and analgesic properties of 5-acyl-arylhydrazone 1-H pyrazolo [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1994, 69, 163-169.	1.2	40
46	Synthesis and analgesic properties of new 4-arylhydrazone 1-H pyrazole [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1996, 71, 213-219.	1.2	39
47	New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2005, 5, 915-926.	1.1	39
48	Microwave-assisted synthesis and structureâ€“activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 74-77.	1.0	39
49	Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064). Polyhedron, 2011, 30, 1891-1898.	1.0	39
50	Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives. Molecules, 2015, 20, 3067-3088.	1.7	39
51	Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists. European Journal of Pharmaceutical Sciences, 2000, 11, 285-290.	1.9	37
52	New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. European Journal of Medicinal Chemistry, 2002, 37, 163-170.	2.6	37
53	Beneficial effects of a novel agonist of the adenosine <scp>A_{2A}</scp> receptor on monocrotalineâ€induced pulmonary hypertension in rats. British Journal of Pharmacology, 2013, 169, 953-962.	2.7	37
54	A utilizaÃ§Ã£o do safrol, principal componente quÃmico do Ã³leo de sassafrÃ¡z, na sÃntese de substÃ¢ncias bioativas na cascata do Ã¡cido araquidÃ´nico: antiinflamatÃ³rios, analgÃ©sicos e anti-trombÃ³ticos. Quimica Nova, 1999, 22, 744-759.	0.3	37

#	Article	IF	Citations
55	New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: Quantitative structureâ€“activity relationship studies. Bioorganic and Medicinal Chemistry, 2005, 13, 6336-6346.	1.4	36
56	Aspectos quÃmicos, biolÃ³gicos e etnofarmacolÃ³gicos do gÃªnero Cassia. Quimica Nova, 2006, 29, 1279-1286.	0.3	36
57	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. International Journal of Cardiology, 2014, 173, 154-162.	0.8	36
58	Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: Orally effective anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 1125-1131.	1.4	35
59	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (â^')-spectaline. European Journal of Pharmacology, 2008, 580, 339-349.	1.7	34
60	EstratÃ©gia de simplificaÃ§Ã£o molecular no planejamento racional de fÃ¡rmacos: a descoberta de novo agente cardioativo. Quimica Nova, 2002, 25, 1172-1180.	0.3	33
61	Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. Journal of Pharmacy and Pharmacology, 2010, 60, 699-707.	1.2	33
62	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. International Journal of Biological Macromolecules, 2016, 82, 663-670.	3.6	33
63	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties. European Journal of Medicinal Chemistry, 2011, 46, 3000-3012.	2.6	32
64	Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco, 1999, 54, 747-757.	0.9	31
65	Adenosine A_{2A} receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Design, Development and Therapy, 2017, Volume11, 553-562.	2.0	31
66	Molecular modeling of novel 1H-pyrazolo[3,4-b]pyridine derivatives designed as isosters of the antimalarial mefloquine. Computational and Theoretical Chemistry, 2002, 579, 31-39.	1.5	28
67	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	1.6	28
68	Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. European Journal of Medicinal Chemistry, 2002, 37, 219-229.	2.6	27
69	Improved Solventâ€Free Dakin Oxidation Protocol. Synthetic Communications, 2008, 38, 784-788.	1.1	27
70	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2017, 8, 858.	1.6	27
71	New optimized piperamide analogues with potent in vivo hypotensive properties. European Journal of Pharmaceutical Sciences, 2004, 23, 363-369.	1.9	26
72	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research, 2013, 237, 86-95.	1.2	26

#	Article	IF	Citations
73	Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. European Journal of Pharmacology, 2010, 638, 5-12.	1.7	25
74	Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR?. Toxicon, 2010, 56, 604-612.	0.8	25
75	Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Journal of Medicinal Chemistry, 2013, 66, 122-134.	2.6	25
76	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	1.0	24
77	Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole. Bioorganic and Medicinal Chemistry, 2009, 17, 6517-6525.	1.4	24
78	Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 183-188.	1.0	23
79	Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives designed as mefloquine analogues. Il Farmaco, 2002, 57, 825-832.	0.9	23
80	Antinociceptive Profile of (-)-Spectaline: A Piperidine Alkaloid fromCassia leptophylla. Planta Medica, 2003, 69, 795-799.	0.7	23
81	Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. Journal of Molecular Modeling, 2012, 18, 2065-2078.	0.8	23
82	Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Il Farmaco, 2002, 57, 999-1007.	0.9	22
83	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of Ì¦B kinase-Î². European Journal of Medicinal Chemistry, 2011, 46, 1245-1253.	2.6	22
84	Discovery of naphthylâ€‹Nâ€‹acylhydrazone p38Î± MAPK inhibitors with in vivo antiâ€‹inflammatory and antiâ€‹TNFâ€‹Î± activity. Chemical Biology and Drug Design, 2018, 91, 391-397.	1.5	22
85	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	1.1	21
86	The Synthesis and Anti-inflammatory Properties of a New Sulindac Analogue Synthesized from Natural Safrole. Journal of Pharmaceutical Sciences, 1992, 81, 1219-1222.	1.6	20
87	LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR. Toxicon, 2011, 58, 195-201.	0.8	20
88	Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues. Molecules, 2012, 17, 14126-14145.	1.7	20
89	LASSBio-468: a new achiral thalidomide analogue which modulates TNF-Î± and NO production and inhibits endotoxic shock and arthritis in an animal model. International Immunopharmacology, 2005, 5, 485-494.	1.7	19
90	Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. Pharmacology Biochemistry and Behavior, 2009, 94, 70-74.	1.3	19

#	Article	IF	Citations
91	Pharmacological Characterization of (3-Thienylidene)-3,4-Methylenedioxybenzoylhydrazide: A Novel Muscarinic Agonist With Antihypertensive Profile. American Journal of Hypertension, 2010, 23, 135-141.	1.0	19
92	Modelagem Molecular: Uma Ferramenta para o Planejamento Racional de FÃ¡rmacos em QuÃmica Medicinal. Quimica Nova, 1997, 20, 300-310.	0.3	18
93	MAOS and Medicinal Chemistry: Some Important Examples from the Last Years. Molecules, 2011, 16, 9274-9297.	1.7	18
94	Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema. Frontiers in Physiology, 2015, 6, 267.	1.3	18
95	Design, synthesis and inÂvitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 2015, 100, 24-33.	2.6	18
96	Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 315-323.	1.3	18
97	Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. European Journal of Medicinal Chemistry, 2009, 44, 3612-3620.	2.6	17
98	The synthesis of a new benzothiazine derivative, related to oxicams, synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1992, 29, 1667-1669.	1.4	16
99	Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 73, 281-292.	1.2	16
100	Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 9-12.	1.0	16
101	Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFÎ± modulators. Bioorganic and Medicinal Chemistry, 2006, 14, 6874-6885.	1.4	16
102	Novel Potent Imidazo[1,2-a]pyridine-N-Glycinyl-Hydrazone Inhibitors of TNF-Î± Production: In Vitro and In Vivo Studies. PLoS ONE, 2014, 9, e91660.	1.1	16
103	Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M^{PRO}) through in silico screening supported by molecular docking and a fragment-based pharmacophore model. RSC Medicinal Chemistry, 2021, 12, 110-119.	1.7	16
104	Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacology Biochemistry and Behavior, 2008, 89, 23-30.	1.3	14
105	Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3734-3736.	1.0	14
106	Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, 2011, 63, 1029-1039.	1.5	14
107	Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists. Current Topics in Medicinal Chemistry, 2012, 12, 2037-2048.	1.0	14
108	Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 264-271.	2.6	14

#	Article	IF	Citations
109	Biotransformation of LASSBio-579 and pharmacological evaluation of p -hydroxylated metabolite a N -phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry, 2013, 62, 214-221.	2.6	14
110	Gastroprotective effects of N-acylarylhydrazone derivatives on ethanol-induced gastric lesions in mice are dependent on the NO/cGMP/KATP pathway. Biochemical Pharmacology, 2019, 169, 113629.	2.0	14
111	Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38Î± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7347-7354.	2.9	14
112	Electrospray ionization mass and tandem mass spectra of a series ofN-pyrazolylmethyl andN-triazolylmethylN-phenylpiperazines: new dopaminergic ligands with potential antipsychotic properties. Journal of Mass Spectrometry, 2005, 40, 815-820.	0.7	13
113	The molecular basis for coxib inhibition of p38Î± MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3506-3509.	1.0	13
114	Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 427-446.	1.2	13
115	LASSBio-1135: A Dual TRPV1 Antagonist and Anti-TNF-Alpha Compound Orally Effective in Models of Inflammatory and Neuropathic Pain. PLoS ONE, 2014, 9, e99510.	1.1	13
116	Characterization of the conformational ensemble from bioactive N-acylhydrazone derivatives. Journal of Molecular Graphics and Modelling, 2010, 28, 446-454.	1.3	12
117	Potential Inhibitory Effect of LASSBio-596, a New Thalidomide Hybrid, on Inflammatory Corneal Angiogenesis in Rabbits. Ophthalmic Research, 2012, 48, 177-185.	1.0	12
118	Structure Re-determination of LASSBio-294 â€“ a cardioactive compound of the N-acylhydrazone class â€“ using X-ray powder diffraction data. Powder Diffraction, 2013, 28, S491-S509.	0.4	12
119	Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes. Chinese Chemical Letters, 2015, 26, 721-726.	4.8	12
120	Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents. Drug Design, Development and Therapy, 2016, Volume 10, 2869-2879.	2.0	12
121	Design and Synthesis of a New 4-Oxa-8.OMEGA.-11-deoxy-5,6-dihydroprostacyclin Analogue.. Chemical and Pharmaceutical Bulletin, 1996, 44, 2157-2161.	0.6	11
122	O-Alkylation of Bioactive Phthalimide Derivatives Under Microwave Irradiation in Dry Media. Synthetic Communications, 2000, 30, 3291-3306.	1.1	11
123	Synthesis of Piperamides and New Analogues from Natural Safrole. Synthetic Communications, 1999, 29, 263-273.	1.1	10
124	SYNTHESIS OF NATURAL AMIDE ALKALOID PIPERDARDINE AND A NEW BIOACTIVE ANALOGUEâ€. Synthetic Communications, 2001, 31, 117-123.	1.1	10
125	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. European Journal of Medicinal Chemistry, 2009, 44, 1959-1971.	2.6	10
126	3-Aminothiophene-2-Acylhydrazones: Non-Toxic, Analgesic and Anti-Inflammatory Lead-Candidates. Molecules, 2014, 19, 8456-8471.	1.7	10

#	Article	IF	Citations
127	Structural characterization of LASSBio-1289: a new vasoactive N-methyl-N-acylhydrazone derivative. CrystEngComm, 2015, 17, 165-173.	1.3	10
128	Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. Journal of Molecular Structure, 2017, 1147, 226-234.	1.8	10
129	Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. PLoS ONE, 2016, 11, e0162895.	1.1	10
130	Chemical Intuition in Drug Design and Discovery. Current Topics in Medicinal Chemistry, 2019, 19, 1679-1693.	1.0	10
131	Synthesis of pyrazole derivatives as potential bioisosteres of thromboxaneâ€synthetase inhibitors. Journal of Heterocyclic Chemistry, 1992, 29, 407-411.	1.4	9
132	New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole. Journal of the Brazilian Chemical Society, 1999, 10, 421-428.	0.6	9
133	Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response. Molecules, 2012, 17, 14651-14672.	1.7	9
134	The Synthesis and Antiinflammatory Activity of 1-Alkyl-Isochroman-1-yl Acetic Acids Derivatives. Journal of the Brazilian Chemical Society, 1993, 4, 40-44.	0.6	9
135	Synthesis of condensed tricyclic pyrazolo[3,4-b]thieno[2,3-d]pyridine and related isostere derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 309-313.	1.4	8
136	The synthesis of new isochromanylacetylarylhydrazones designed as probable non-addictive analgesic agents. Journal of the Brazilian Chemical Society, 1997, 8, 471-478.	0.6	8
137	Anti-inflammatory Profile of N-Phenylpyrazole Arylhydrazone Derivatives in Rats. Journal of Pharmacy and Pharmacology, 2010, 51, 703-707.	1.2	8
138	Antihyperalgesic effects of a novel muscarinic agonist (<scp>LASSB</scp>ioâ€873) in spinal nerve ligation in rats. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 404-411.	0.9	8
139	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	1.1	8
140	Synthesis of new 1,2-Benzothiazin-3-one Derivatives Designed as Dual Cyclooxygenase-2 and 5-Lipooxygenase Inhibitors. Journal of the Brazilian Chemical Society, 1998, 9, 119-130.	0.6	7
141	Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2888-2891.	1.0	7
142	CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. European Journal of Medicinal Chemistry, 2011, 46, 349-355.	2.6	7
143	Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LCâ€“MS/MS: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1024-1030.	1.4	7
144	LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349.	0.8	7

#	Article	IF	Citations
145	Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative. Pharmaceuticals, 2018, 11, 119.	1.7	7
146	LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice. European Journal of Pharmacology, 2019, 863, 172662.	1.7	7
147	Synthesis and Anti-Platelet Evaluation of New Tricyclic PAF Antagonists, Designed as Structurally Related to Hetrazepine Class - Web 2086. Journal of the Brazilian Chemical Society, 1996, 7, 247-256.	0.6	7
148	Synthesis of New Benzylic Ethers of Oximes Derived from 1-Phenyl-pyrazole Compounds. Synthetic Communications, 1998, 28, 1299-1321.	1.1	6
149	Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 101-109.	2.5	6
150	Structural feature evolution â€“ from fluids to the solid phase â€“ and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative. RSC Advances, 2015, 5, 39889-39898.	1.7	6
151	Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction. International Immunopharmacology, 2018, 65, 108-118.	1.7	6
152	Comparative chemical and biological hydrolytic stability of homologous esters and isosteres. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 718-727.	2.5	6
153	What is hidden in the biodiversity? The role of natural products and medicinal chemistry in the drug discovery process. Anais Da Academia Brasileira De Ciencias, 2019, 91, e20190306.	0.3	5
154	Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats. Pharmacological Reports, 2019, 71, 1190-1200.	1.5	5
155	Toward a platelet-activating factor pseudoreceptor: Semiempirical modeling of cation-Ï€ and hydrogen bond interactions in agonist binding. Computational and Theoretical Chemistry, 1998, 429, 217-227.	1.5	4
156	Novel Agonist of Adenosine Receptor Induces Relaxation of Corpus Cavernosum in Guinea Pigs: An InÂVitro and InÂVivo Study. Urology, 2015, 85, 1214.e17-1214.e21.	0.5	4
157	Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 62, 1-6.	2.5	4
158	Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized. Toxicon, 2018, 144, 75-82.	0.8	4
159	Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization. Letters in Drug Design and Discovery, 2018, 15, 778-786.	0.4	4
160	New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis . Drug Design, Development and Therapy, 2020, Volume 14, 3337-3350.	2.0	4
161	Novel phosphatidylinositol 4-kinases III beta (PI4KIIIÎ²) inhibitors discovered by virtual screening using free energy models. Journal of Computer-Aided Molecular Design, 2020, 34, 1091-1103.	1.3	4
162	The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies. Letters in Drug Design and Discovery, 2007, 4, 422-425.	0.4	3

#	Article	IF	Citations
163	A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug. Journal of Molecular Structure, 2017, 1146, 735-743.	1.8	3
164	The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology, 2017, 69, 1374-1380.	1.2	3
165	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1073-1088.	0.3	3
166	Novel VEGFRâ€2 inhibitors with an Nâ€acylhydrazone scaffold. Archiv Der Pharmazie, 2020, 353, e2000130.	2.1	3
167	Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. European Journal of Pharmacology, 2005, 511, 219-227.	1.7	2
168	Synthesis and characterization of the atropisomeric relationships of a substituted Nâ€phenylâ€bipyrazole derivative with antiâ€inflammatory properties. Chirality, 2012, 24, 463-470.	1.3	2
169	In vivo effect of LASSBio-785, a lipid-lowering and anti-inflammatory agent, on cardiac Ca2+-ATPases from hypercholesterolemic rats. International Journal of Cardiology, 2015, 201, 282-284.	0.8	2
170	Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Frontiers in Pharmacology, 2019, 10, 628.	1.6	2
171	Carbamoyl-N-aryl-imine-urea: a new framework to obtain a putative leishmanicidal drug-candidate. RSC Advances, 2020, 10, 12384-12394.	1.7	2
172	Synthesis and Pharmacological Evaluation of Novel Antinociceptive N-Substituted-phenylimidazolyl-4-acylhydrazone Derivatives.. ChemInform, 2003, 34, no.	0.1	0
173	1-Methyl-7-(4-nitrophenyl)-3-phenylpyrazolo[3,4-b]pyrrolo[3,4-d]pyridine-6,8(3H,7H)-dione. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2356-o2356.	0.2	0
174	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. Topics in Medicinal Chemistry, 2020, , 155-201.	0.4	0
175	Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514. Molecules, 2021, 26, 4828.	1.7	0
176	Effect of Sâ€“Se Bioisosteric Exchange on Affinity and Intrinsic Efficacy of Novel N-acylhydrazone Derivatives at the Adenosine A2A Receptor. Molecules, 2021, 26, 7364.	1.7	0